Transoral robotic surgery showed good oncologic, functional outcomes

Source: Author: Christen Haigh Patients with head and neck cancers treated with transoral robotic surgery — or TORS — had good disease control, disease free survival (DFS) and overall survival (OS), according to the findings of a preliminary study presented at the Multidisciplinary Head and Neck Cancer Symposium in Chandler, Ariz. “Disease control and survival rates using TORS appeared to be equivalent or near equivalent to those rates reported with chemoradiation, but with TORS, we need better functional outcome,” Eric Genden, MD, chief of the division of head and neck oncology at Mount Sinai Medical Center, New York, said during the presentation of the results. To determine the role of TORS in the treatment of oropharyngeal cancer, researchers prospectively evaluated patterns of failure, survival and functional outcomes of 25 patients treated with TORS and compared them with that of 12 patients treated with combined chemoradiation. The one-year locoregional control was 95%; distant control was 96%; DFS was 86% and OS was 86%. There was one local failure, one distant failure, one second primary failure and one comorbid death. Patients who received TORS had less acute toxicity two weeks after treatment vs. patients who received chemoradiotherapy. The TORS group had better eating ability than the chemoradiotherapy group (74% vs. 52%) and had improved diet vs. the chemoradiotherapy group (43% vs. 20%). Thus, TORS was associated with a higher overall functional oral intake scale score vs. that of the chemoradiotherapy group (5.3 vs. 3.2). Both groups had a score of 100% for [...]

Cetuximab continues to increase survival in patients with head and neck cancer for up to 5 years

Source: www.docguide.com Author: staff Adding cetuximab to radiation therapy prolongs survival in patients with locally advanced head and neck cancer compared with radiotherapy alone, and this improvement persists for up to 5 years. As such, this combined treatment should be considered as a standard option for patients with advanced head and neck cancer, according to a study published online first and appearing in an upcoming issue of The Lancet Oncology. The use of chemoradiotherapy has been shown to improve survival and has become a popular treatment, but is not ideal because of its associated side-effects and increased toxicity. In 1999, a trial commenced to examine the effect of adding cetuximab to radiotherapy in patients with locally advanced head and neck cancers of the oropharynx, hypopharynx, and larynx. In total, 424 patients were randomly assigned to 6 to 7 weeks of radiotherapy alone (n = 213) or radiotherapy and cetuximab (n = 211). The primary results of the trial showed that patients treated with cetuximab had a 13% improvement in absolute disease control and 10% improvement in absolute survival at 3 years without increased side-effects, compared with patients given radiotherapy alone. In the current article, James Bonner, MD, University of Alabama, Birmingham, Alabama, and colleagues reported the long-term 5-year outcomes of patients involved in the original trial. Overall, findings showed an improvement in absolute survival of about 9% in patients given cetuximab compared with those given radiotherapy alone (36.4% vs 45.6%) at 5 years. Interestingly, patients treated with cetuximab who developed [...]

2009-11-07T11:26:48-07:00November, 2009|Oral Cancer News|
Go to Top